ARBUTUS BIOPHARMA CORP (ABUS) Stock Income Statement
NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.17M | 18.14M | 39.02M | 10.99M | 6.91M | |||
| Operating Expenses | 78.77M | 96.24M | 104.48M | 84.51M | 64.66M | |||
| Research and Development | 54.04M | 73.70M | 84.41M | 65.50M | 47.48M | |||
| Selling, General, and Administrative Expenses | 22.11M | 22.48M | 17.83M | 17.14M | 14.72M | |||
| Operating Income | -72.60M | -78.10M | -65.46M | -73.52M | -57.75M | |||
| Interest Income/Expense | 6.40M | 5.25M | 440.00K | -2.73M | -5.94M | |||
| Non Recurring Items | -3.72M | N/A | N/A | 0.00 | -60.00K | |||
| Income Before Taxes | -69.92M | -72.85M | -65.01M | -76.25M | -63.75M | |||
| Income Tax | 0.00 | 0.00 | 4.44M | N/A | 0.00 | |||
| Net Income | -69.92M | -72.85M | -69.46M | -88.39M | -75.87M | |||
| EBITDA | -71.22M | -76.70M | -64.03M | -71.77M | -55.77M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.38 | -0.44 | -0.46 | -0.83 | -1.00 | |||
| Non GAAP EPS | -0.37 | -0.44 | -0.47 | -0.83 | -1.00 | |||
| Statistics | ||||||||
| Profit Margin | -1133.04% | -401.57% | -178.01% | -804.28% | -1097.97% | |||
| Operating Profit Margin | -1176.45% | -430.53% | -167.76% | -668.97% | -835.75% | |||
All data in USD